Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.

Autor: Xu C; Public Health Research Institute, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA., Wang A; Public Health Research Institute, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA., Honnen W; Public Health Research Institute, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA., Pinter A; Public Health Research Institute, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA., Weston WK; Innovation Pharmaceuticals, Inc., Wakefield, Massachusetts, USA., Harness JA; Innovation Pharmaceuticals, Inc., Wakefield, Massachusetts, USA., Narayanan A; National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, Virginia, USA., Chang TL; Public Health Research Institute, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA.; Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA.

Publikováno v: EC microbiology [EC Microbiol] 2022 Apr; Vol. 18 (4), pp. 1-12. Date of Electronic Publication: 2022 Mar 08.